Oxytocin-Gly-Lys-Arg: A Novel Cardiomyogenic Peptide by Danalache, Bogdan A. et al.
Oxytocin-Gly-Lys-Arg: A Novel Cardiomyogenic Peptide
Bogdan A. Danalache
1, Jolanta Gutkowska
1,2, Magdalena J. S ´lusarz
3, Irena Berezowska
4, Marek
Jankowski
1,2*
1Research Centre, Centre Hospitalier de l’Universite ´ de Montre ´al (CRCHUM) – Ho ˆtel-Dieu, Montreal, Quebec, Canada, 2Department of Medicine, Universite ´ de Montre ´al,
Montreal, Quebec, Canada, 3Faculty of Chemistry, University of Gdan ´sk, Gdan ´sk, Poland, 4Laboratory of Chemical Biology and Peptide Research, Clinical Research
Institute of Montreal, Montreal, Quebec, Canada
Abstract
Background: Oxytocin (OT), synthesized in the heart, has the ability to heal injured hearts and to promote
cardiomyogenesis from stem cells. Recently, we reported that the OT-GKR molecule, a processing intermediate of OT,
potently increased the spontaneous formation of cardiomyocytes (CM) in embryonic stem D3 cells and augmented glucose
uptake in newborn rat CM above the level stimulated by OT. In the present experiments, we investigated whether OT-GKR
exists in fetal and newborn rodent hearts, interacts with the OT receptors (OTR) and primes the generation of contracting
cells expressing CM markers in P19 cells, a model for the study of early heart differentiation.
Methodology/Principal Findings: High performance liquid chromatography of newborn rat heart extracts indicated that
OT-GKR was a dominant form of OT. Immunocytochemistry of mouse embryos (embryonic day 15) showed cardiac OT-GKR
accumulation and OTR expression. Computerized molecular modeling revealed OT-GKR docking to active OTR sites and to
V1a receptor of vasopressin. In embryonic P19 cells, OT-GKR induced contracting cell colonies and ventricular CM markers
more potently than OT, an effect being suppressed by OT antagonists and OTR-specific small interfering (si) RNA. The V1a
receptor antagonist and specific si-RNA also significantly reduced OT-GKR-stimulated P19 contracting cells. In comparison to
OT, OT-GKR induced in P19 cells less a-actinin, myogenin and MyoD mRNA, skeletal muscle markers.
Conclusions/Significance: These results raise the possibility that C-terminally extended OT molecules stimulate CM
differentiation and contribute to heart growth during fetal life.
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Introduction
Oxytocin (OT), recognized as a female reproductive hormone,
is largely produced in hypothalamic magnocellular neurons of
paraventricular and supraoptic nuclei. Biochemical and recombi-
nant DNA studies have demonstrated that it is synthesized as the
non-glycosylated protein, which undergoes an initial endoproteo-
lytic cleavage by the convertase magnolysin (EC 3.4.24.62) to OT-
Gly-Lys-Arg (OT-GKR) [1,2]. Subsequent processing produces
other OT extended molecules: OT-Gly-Lys (OT-GK) and OT-
Gly (OT-G) [2], often referred to as OT-X [3].
OT-G is converted by an a-amidating enzyme to C-amidated
nonapeptide which is released into the circulation in this form.
OT-X forms have been detected in the developing brain of
animals and in fetal plasma. In rats, enzymatic OT-X conversion
to OT is almost complete in adulthood, but not in fetuses, which
accumulate OT-X in the brain [4,5]. Similarly, the plasma OT-X
elevation reported during early fetal development in sheep [3] is
reduced in late gestation, when OT begins to predominate in the
circulation.
OT’s acts on only one type of OT receptor (OTR), an integral
membrane protein that is a member of the rhodopsin-type (class I)
G protein-coupled receptor family, which includes arginine
vasopressin (AVP) receptor subtypes (V1aR, V1bR and V2).
The peptide sequences of AVP and OT differ only in 2 amino
acids in positions 3 and 8, which enable these hormones to interact
with the respective receptors [6]. OTR and OT biosynthesis is
detected in the atria and ventricles of the heart, and OT is thought
to be involved in atrial natriuretic peptide (ANP) release from the
cardiomyocytes (CM) of newborn rats [7,8] and humans [9].
Indeed, OTR immunostaining of the heart is predominantly
detected in CM [10]. Because radioimmunoassay (RIA) indicates
OT elevation in fetal and newborn hearts at a stage of intense
cardiac hyperplasia, we hypothesized a role for OT in CM
differentiation [8]. Our initial experiments demonstrated that OT
induces CM differentiation of the mouse embryonal carcinoma
(EC) P19 cell line, a common cell model for studying early heart
differentiation [11]. Several reports have confirmed OT-stimulat-
ed cardiomyogenesis in different lines of embryonic stem (ES) cells
[12,13,14]. Some of these observations pointed to a Ca
2+
mobilization mechanism in response to OT treatment in ES D3
cells differentiating into CM [15]. We established that the OTR-
nitric oxide-cGMP pathway is essential for the OT-elicited
differentiation of P19 stem cells into CM in association with
elevation of transcription factors GATA-4 and myocyte-specific
enhancer factor 2c (Mef2c) [12]. More recently, we obtained
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treatment with OT-GKR stimulated glucose uptake in rat CM
[16] and enhanced spontaneous cardiomyogenesis of ES D3 cells
more potently than OT nonapeptide [15].
In the present study, we reasoned that if OT-GKR plays a role
in cardiomyogenesis we should detect the molecule in fetal and
newborn animal hearts. To investigate whether the biological
actions of OT-GKR are mediated by the OTR, the interactions of
these molecules were analyzed by computer-generated 3D models.
Because EC P19 cells do not spontaneously differentiate into CM
after their aggregation in the presence of fetal calf serum [11], as
has been observed for ES D3 cells [15], therefore we used these
cells to analyze whether OT-GKR treatment generate the
contracting colonies expressing CM markers. The specificity of
this reaction was examined by inhibition by OT antagonists
(OTA) and OTR suppression by specific small interfering RNA
(siRNA) and similar condition was investigated for V1aR.
Results
OT-GKR is the dominant OT form in developing hearts
Synthetic OT-X molecules and OT were used to identify
elution profiles from the HPLC column. Specific wavelength
intervals at 215 and 280 nm were calibrated by spectrophotom-
etry. Subsequently, HPLC-specific retention factor for OT
standards was k’=0.67 for OT, k’=1.34 for OT-GKR,
k’=1.67 for OT-GK, and k’=2.01 for OT-G. Similar retention
factors of these molecules have been disclosed in heart extracts
from newborn rats. Analysis of eluates, released from the column,
revealed a small peak at k’=0.67, corresponding to OT, and a
large second peak at k’=1.34, calibrated as a retention factor of
OT-GKR. A minor peak was observed at k’=1.67, the point of
OT-GK elution, and a minimal peak, if any, was detected at the
point of elution of OT-G. The presence of OT-GKR in specific
HPLC fractions was confirmed by specific RIA with antibodies
specific for OT and antibodies detecting OT-X forms.
Immunocytochemistry reveals OT-GKR in developing
hearts
Immunocytochemistry of whole mouse embryos (embryonic day
15) demonstrated the entire OT system in somites, mesoderm
masses distributed along neural tubes and developing into the
dermis, skeletal muscle and vertebrae. As shown in Figure 1A,
significant OT-GKR expression was found inside, whereas OT
nonapeptide (Fig. 1B) and OTR (Fig. 1C) were viewed on the
periphery of somites showing apoptosis (Fig. 1D). Control staining
with OT-GKR-specific antibody, pre-absorbed with OT-GKR,
was negative in somites (Fig. 1E) as well as in whole mouse sections
(Fig. 1F). In sections stained with OT-GKR antibody, intense
brown staining was observed in fetal hearts (Fig. 1G and 1H).
Double staining by immunofluorescence indicated OT-GKR
deposits in cells stained with the CM marker troponin C
(Fig. 1I). Fetal heart sections were also stained with anti-OTR
antibody (Fig. 1J) and with anti-OT antibody the staining was
barely visible (Fig. 1K). Immunostaining with anti-vasopressin
(Fig. 1L) was negative and some staining was found with anti-
V1aR antibody (Fig. 1M). No staining was seen in the
corresponding negative control (Fig. 1N).
Docking analysis shows OT-GKR interaction with OTR
Because of significant molecular differences between OT-GKR
and OT, the question has been raised whether OT-GKR interacts
with OTR binding sites. For this reason, we performed
computational docking analysis of OT molecules in OTR binding
sites. Figure 2 illustrates the docking of 3-D human OTR with
OT-GKR and OT-modeled molecules in front upright view
(Fig. 2A) and a view from the extracellular side (Fig. 2B). Three
conformations for both OT-GKR and OT were analyzed. Six
related receptor-Ga-segment-OT-GKR complexes were obtained.
Possible hydrophobic and electrostatic interaction points in
dynamic complexes of these molecules were indicated by estimated
binding affinity energies of 26.660.4 kJ/mol for OT-GKR and
211.860.6 kJ/mol for OT. Using distance criteria, the program
identified receptor amino acid residues interacting with ligands.
The essential hydrogen bond and strong electrostatic interactions
between both OT molecules and the receptors were characterized
by visual inspection. The results are reported in Figure 2D and
Table 1. Several amino acid residues have been proposed to
interact with OT and OT-GKR in the OTR model where the red
bars represent docking with OT-GKR, and the black bars indicate
docking with OT molecule (Fig. 2D). Docking to OTR in positions
V115, K116, Q119, M123, Q171, F185, T205, Y209 and Q295
was noted for both OT and OT-GKR models (Table 1). These
docking positions constituted 42% of all observed docking sites of
OT-GKR. Among OT-GKR interactions, the special notice
should be given to binding of the arginine-12 (R12), (Fig. 2 D) to
OTR. We also analyzed the docking of OT-GKR and OT
molecules in the 3-D human V1aR model molecules were similar
binding affinity energies of -7,3860.3 kJ/mol for OT-GKR and
211,1160.6 kJ/mol for OT. Figure 2E and Table 1 show OT-
GKR and OT docking at respective binding sites. Both molecules
were docked in positions of Q104, K128, Q311, L335, S338 and
N340. The OT-GKR was bound exclusively in positions of G134,
S138 and A299.
OT-GKR stimulates contracting cell colonies in EC P19
cells
EC P19 cell cardiogenic differentiation is not spontaneous or
very rare. With the hanging drop method in the presence or
absence of inducers, EC P19 embryoid bodies (EBs) were analyzed
for their beating activity from day 2 until 14 after plating. In cell
cultures not exposed to inducers (NI) no beating cell colonies were
found (Fig. 3A), although they sometimes displayed rare beating
foci. We chose micromolar concentrations to compare the action
of OT and OTX forms. The 10
26 M concentration was found to
be the most efficient in inducing cardiomyogenesis. As with OT
treatment, extended OT forms induced the appearance of
numerous colonies, with cell-specific organization, in linear,
parallel arrays or round clusters displaying synchronized contrac-
tions (Fig. 3B-E). Videoanalysis revealed that OT and OT-X were
equally efficient in producing beating cell colonies by day 14
(Fig. 3F). However, observations on day 8 disclosed a significantly
larger number of contracting cell colonies in samples induced by
OT-GKR (960.6) compared to cells induced by OT (560.4), OT-
G( 4 60.6) or OT-GK (760.6), p,0.05.
To ascertain OTR involvement in OT-GKR-mediated cardi-
omyogenesis, OT-GKR-treated EBs were additionally exposed to
10
26 M OTA (Fig. 3F). Indeed, OTA effectively inhibited the
number of OT-GKR-stimulated contracting colonies (2603 foci
in 24 wells at day 8, and 460.6 at day 12) vs. OT-GKR (2360.2/
24 at day 12, p,0.05). Application of V1R antagonist also
diminished the number of beating cells induced by OT-GKR (to
2603 foci in 24 wells at day 8 and 860.6 at day 12, p,0.05),
indicating that both OTR and V1aR contribute to the generation
of contracting cell colonies.
To verify receptor function in the cardiomyogenesis of EC P19
cells, we used specific siRNA for OTR and V1aR silencing. As
illustrated in Figure 3G, OTR staining with OTR antibody
Oxytocin in the Heart
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for V1aR was presented in the Fig. 3I. This was significantly
reduced in cells subjected for the both siRNA treatments (OTR -
Fig. 3H, respectively V1aR - Fig. 3J). Consequently, in siRNA-
treated cells at day 12, OT-GKR treatment resulted in the
production of very small clusters of weakly beating cells in only
Figure 1. Detection of the OT system in the E15 mouse embryo by immunocytochemistry. Somite staining with OT-GKR antibody (A) and
selective antibodies for OT (B) and OTR (C). TUNEL reaction displaying apoptosis (D). Control staining of somites with OT-GKR-specific antibody
reabsorbed with OT-GKR (E) Control staining of whole embryo with OT-GKR-specific antibody reabsorbed with OT-GKR (F). Immunodetection of OT-
GKR in the fetal mouse heart at day E15 (arrow) (G). Polyclonal rabbit antibody specifically recognizing OT-GKR peptide was applied to detect OT-
GKR. Staining was revealed by the biotin-streptavidin method. Higher magnification of OT-GKR staining in the fetal heart (H). Immunofluorescence of
OT-GKR (Texas Red) in cryostat sections section of cardiac tissue (stained green by troponin Alexa Fluor 488 antibody) by (I). Immunodetection in the
heart of OTR (J), OT (K), AVP (L), and V1R (M). Control staining with OT-GKR-specific antibody reabsorbed with OT-GKR (N).
doi:10.1371/journal.pone.0013643.g001
Oxytocin in the Heart
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cell colonies (Fig. 3I), p,0.05. Application of siV1aR also
diminished the number of beating cells induced by OT-GKR (to
260.2 foci in 24 wells at day 8, 661.0 at day 12, p,0.05)
indicating that both OTR and V1aR contribute to generation of
contracting cell colonies and CM differentiation.
Because OT-GKR accumulation in fetal hearts was seen inside
cells expressing the CM marker, we investigated whether the
endogenous production of OT-GKR in EC P19 cells initiates
cardiomyogenesis. For this purpose, the cardiogenic potency of
OT-GKR was studied in EC P19 cells stably expressing the
pcDNA3.1/Amp-OT-GKR-IRES/EGFP (green fluorescence)
construct (Fig. 4A). As shown in Figure 4B-E, OT-GKR protein
was disclosed by immunofluorescence in approximately 30% of
transfected cells. Although at day 12, the beating cell colonies
induced by endogenous OT-GKR were fewer (10/2460.4) than
those receiving OT-GKR from the medium (21/2460.6,
p,0.05), the OT-GKR-transfected cells displayed large clusters
of beating activity (Fig. 4F).
For the quantitative assessment of cardiomyogenic differentiation,
the EGFP expression pattern in P19Cl6-GFP cells was analyzed by
fluorescence microscopy and flow cytometry. Figure 5 characterizes
the cells derived from EBs at day 8, representing the early
cardiomyoblast stage. Brilliant GFP fluorescence indicated the
expression of the specific ventricular marker MLC-2v. At day 8,
GFP-positive areas were absent in NI cells (Fig. 5A), whereas cells
i n d u c e db yO T( F i g .5 B )a n dO T - X( F i g s .5 C - E )e x h i b i t e di d e n t i c a l ,
intense GFP fluorescence. However, flow cytometry analysis (illus-
trated in Figs. 5A1-E1) demonstrated a significantly larger number of
GFP-positive cells upon OT-GKR stimulation in comparison to
stimulation with OT, OT-G or OT-GK (Fig. 5F, p,0.05).
OT-GKR induces differentiation markers in EC P19 cells
Cardiac and skeletal markers were altered during OT-mediated
cell differentiation. Figure 6 illustrates the expression of genes at
the 6
th day of EC P19 cell differentiation, when the first beating
cell colonies were detected. Exposure of EC P19 cells to OT and
OT-GKR increased GATA-4 mRNA (Fig. 6A), the transcription
factor involved in cardiac development, and Mef2c mRNA
(Fig. 6B), the gene involved in cardiac morphogenesis and
myogenesis. As shown in Figures 6C and 6D, treatment also
induced the mRNA genes involved in skeletal muscle morpho-
genesis, myogenin mRNA (Fig. 6C) and MyoD mRNA (Fig. 6D).
Interestingly, the expression of these markers was higher in OT-
induced cells than in cells stimulated by OT-GKR. Induction of all
tested mRNA by OT-GKR was reduced in the presence of OTA
to the level seen in NI controls (Fig. 6A-D).
Thedifferentiation process incellsinducedbyOT andOT-GKR
was indicated by loss of OCT-4 immunostaining, a marker of the
undifferentiatedstate (Figs.7A-A4).Cellstreated withOT(Fig.7B2)
or OT-GKR (Fig. 7B3) displayed DHPRa markers of the advanced
contractile apparatus and cardiac transcription factor MLC-2v,
marker of the ventricular phenotype (Figs. 7C2 and 7C3).
Sarcomeric a-actinin, the marker of both skeletal and cardiac
muscles, was produced in larger quantities by cells treated with OT
(Fig. 7D2) than those stimulated with OT-GKR (Fig. 7D3).
Discussion
This study reports original observations that: (i) Fetal mouse and
newborn rat hearts produce the OT-GKR molecule in cells
expressing the CM marker troponin C; (ii) Experiments on EC
P19 cells, the model of early heart differentiation, demonstrate the
Table 1. List of the OTR, V1aR residues, involved in the List of
the OTR interactions with OT-GKR, and OT; * - AVP agonist
binding site; ** - OTA antagonist binding site.
OTR V1aR
OT OT-GKR OT OT-GKR
TM2 - D85 V100 -
- Q92 Q104 Q104* TM2
V115** V115 Q108 -
K116** K116 V127 -
Q119 Q119 K128 K128
TM3 - L118 Q131 -
M123 M123 V132 - TM3
- F124 - G134
S126 - M135 -
- S168 - -
TM4 Q171 Q171 - S138
- I174 L181 -
- E179 S182 - TM4
V184 - Q185 -
F185 F185 Y216 -
- Q193 V217 - TM5
- I201 M220 -
T202 - F225 -
T205 T205 - A299
L206 - F307 - TM6
TM5 Y209 Y209 Q311 Q311*
Q295 Q295 I330 -
V294 - A334 -
TM6 - C287 L335 L335 TM7
F284 - S338 S338
A310** - N340 N340
I313** -
V314** -
TM7 A318 -
- S319
- N321
doi:10.1371/journal.pone.0013643.t001
Figure 2. Molecular docking of 3-D models of activated human OTR and V1aR with OT/OT-GKR peptides obtained by the MolDock
Optimizer algorithm from Molegro Virtual Docker. (A) The front upright view position (side view) of the OTR-OT- GKR complex structure. (A1)
The section (rectangle) shown in panel A1 from the top a intracellular view (i.e. rotation by 90u out of plane) of the marked section in A, demonstrate
OT-GKR (green) in active conformation inside the OT binding site (the transmembrane helices in red and the cavity in violet). (B) side view of the
V1aR-OT- GKR complex, (B1) V1aR top view. (C1) detail of docking view of OTR-OT-GKR complex, and (C2) detail of V1aR-OT-GKR complex. D displays
the schematic model of human OTRs with marked amino acid residues that are putatively involved in ligand-binding. The amino acid residues in
black circles have been proposed as OT docking sites, and the red bars represent docking sites of OT-GKR. (E) Schematic model of human vasopressin
V1aR binding with OT-GKR and OT. Amino acid residues are identified by a 1-letter code in Table 1.
doi:10.1371/journal.pone.0013643.g002
Oxytocin in the Heart
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show cultures at day 10 with dotted lines encircling beating colonies and induced by: (A) Non-inducer, (B) OT, (C) OT-G, (D) OT-GK, (E) OT-GKR. (F)
Time course of appearance of beating cell colonies. At day 5, cultures were transferred into a 24-well tissue culture dish and scored every 2 days for
the presence of beating cell colonies. The generation of beating cell colonies was induced by treatment of EBs (from day 1 to 4) with OT, OT-G, OT-GK
or OT-GKR in the presence of antagonists for OTR and V1aR (see Materials and Methods). The results are expressed as means 6 SEM of 3 independent
experiments. All treatments produced significantly different numbers of beating cell colonies than non-induced controls (NI). G demonstrates OTR
immunodetection in cells at day 2 in control EC P19 cultures and (H) in cells subjected to OTR
2/2 siRNA treatment, (I) detection of V1aR in control,
and (J) in these cells subjected to V1aR
2/2 siRNA treatment. (K) OTR and V1aR inhibition by siRNA in EC P19 cells decreases their ability to generate
beating cell colonies after induction with OT-GKR (10
26 M). *p,0.05, NI – not induced control.
doi:10.1371/journal.pone.0013643.g003
Oxytocin in the Heart
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aggregates treated with OT-GKR protein or in cells transfected
with the DNA construct carrying OT-GKR sequences; (iii)
Computer modeling indicates OT-GKR interaction with the
model of OTR via several amino acid residues, overlapping in
25% of OT binding sites; (iv) The inhibition of OT-GKR
cardiomyogenesis in EC P19 cells by OTA and OTR-specific
siRNA further confirms the role of OTR; (v) The interaction of
OT-GKR with the V1aR model and the partial inhibition of OT-
GKR-mediated stimulation of beating cell colonies in EC P19 cells
by AVP antagonist and V1aR-specific si-RNA suggest that the
OT-GKR can bind to and activate V1aR as well as OTR.
Our previous data indicated that extended OT forms could be
produced in the developing heart since OT synthesis was seen in
CM cultures from newborn rats [8] and in EC P19 cells [12]. In
the present study, HPLC analysis of newborn rat hearts and
immunocytochemistry of whole mouse embryos revealed that OT-
GKR is abundant in developing rodent hearts. The selectivity of
OT-GKR antibodies and the lack of their reaction with OT
nonapeptide have already been demonstrated by RIA cross-
reactivity analysis [15]. Moreover, confocal microscopy in D3
stem cells producing OT-GKR from transfected cDNA constructs
further indicated positive reactions with anti-OT-GKR but
negative reactions with anti-OT antibodies [15]. On the other
hand, recent data suggest the positive effects of OT on osteoblast
development, together with bone formation defects of OT and
OTR deficiency [17]. In the present study, localization of the OT
system in somites, embryonic vertebral precursors, is consistent
with findings that OT is involved in osteogenesis and is important
in skeleton mineralization [17,18]. This result provides further
evidence that identification of the OT system in fetal hearts is
specific and not due to methodological aberrations.
We have already reported that OT-GKR increases cytosolic
Ca
2+ in ES D3 cells [15]. Among receptors of neurophyseal
hormones, this effect is attributed to OTR and V1aR, whereas
V2R is coupled with adenylate cyclase and the second messenger
cAMP [6]. Moreover, all of these receptors have the ability to bind
AVP and/or OT with varying affinities. Thus, both ligands are
capable of initiating signaling cascades mediated by either receptor
[19]. In fact, our studies indicate involvement of NO synthases in
the CM differentiation mediated by OT [12] as well as AVP [20].
This suggests physiological relevance of both OT and AVP
systems and its versatility in the cardiomyogenesis. Early studies
had demonstrated that eNOS favors the maturation and
cardiomyogenesis of murine embryoid bodies in vitro, because
chronic NOS inhibition in these embryonic cells with the guanylyl
cyclase inhibitor,
1H-[1,2,4]oxadiazolo-[4,3-a]-quinoxalin-1-one
(ODQ), resulted in differentiation arrest; the event reversed upon
incubation with the NO donor [21]. Likewise, NO donors and
human iNOS-gene adenoviral transfection in mouse embryonic
stem cells cultured in embryoid bodies facilitated their differen-
tiation into beating cardiomyocytes [22]. OT signaling targeting
eNOS is generally activated through a PLC/calcium/calmodulin
pathway [23], but eNOS activation may also occur via the
phosphatidylinositol-3-kinase (PI-3-K)/AKT pathway [24] as has
been found in endothelial cells [25] and in CM [16,26]. This raises
the possibility of NO being a critical OT signaling molecule for
both the preservation of cardiac cells and the differentiation of
cardiac stem cells reserve. In P19 cells expressing GFP under a
cardiac-specific promoter to monitor their CM differentiation, NO
Figure 4. Schematic structure of the OT-GKR-IRES-EGFP DNA construct. Abbreviations: CMV, cytomegalovirus; EGFP, enhanced green
fluorescent protein; OT, oxytocin. (A) pcDNA3.1/Amp-OT-GKR-IRES-EGFP transfection to EC P19 cells stimulates the expression of green fluorescence
(B) and produces OT-GKR protein marked with VA-18 antibody in red (Texas Red) (C). Blue DAPI staining of cell nuclei (D) and merged photo (E).
Time course of appearance of beating cell colonies in non-induced EC P19 cells transfected with OT-GKR-IRES-EGFP and in normal EC P19 cells
stimulated with OT-GKR (10
26 M), and non-induced controls (NI) (F).
doi:10.1371/journal.pone.0013643.g004
Oxytocin in the Heart
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cGMP-dependent protein kinase G [12]. Recent study indicate that
NO pathways that promote CM differentiation include repression
of self-renewal genes, such as NANOG, and increase in differen-
tiation genes such as GATA4 [27]. During proliferation of
HUVEC, calcium mobilization in response to OT treatment seems
to be instrumental intheactivation of the NOpathway, as shown by
the dramatic reduction of OT-induced NO release when calcium is
chelated [28]. We demonstrated that in CM, chelation of
intracellular calcium by BAPTA, and inhibition of calmodulin
kinase II dramatically reduced the OT-mediated glucose uptake
[16]. Ca
2+ mobilization study in D3 cells showed functional OT-
GKR and OT activity in embryonic stem cells [15]. The observed
sustained effect on Ca
2+ may be due to the nature of both peptides.
In support of this notion, prolonged and long-lasting Fura-2
mobilization of Ca
2+ was demonstrated in cardiac cells in response
to AVP [29,30]. Further data suggest that an activation of OTR
provide a local Ca
2+ signal that induces eNOS activation [15] and
possibly natriuretic peptides [11]. By comparison, the guanylyl
cyclase receptors of natriuretic peptides generate cGMP that can
also contribute to CM differentiation from embryonic stem cells
[31]. The increase in the mRNA expression of the cardiac-specific
transcription factor Nkx2.5 and cardiac markers MLC2 and MHC
followed treatment of embryonic stem cells with NO donors and
cGMP activators [32]. In our previous studies in P19 cells, the
GATA4 expression was only moderately reduced when l-NAME
was administered together with OT, but the transcription factors
MEF2c and Nkx2.5 were extensively downregulated. This lack of
balance of transcription factors can severely impair the cardiomyo-
genic program, which requires physical interaction and synergistic
modulation of target gene expressions [33,34]. The differences in
the expression of myogenic regulatory factors, MyoD and
myogenin, as well as GATA4 and MEF-2, in response of P19 cells
to OT and OT-GKR stimulation, can influence the developmental
decisions of stem cells differentiating into the skeletal or cardiac
muscle lineage. Indeed, the difference a-actin expression in OT and
OT-GKR-differentiated P19 might be directly relatedto the level of
myogenic regulatory factors promoting skeletal muscle lineage [35].
We performed computerized docking analysis to assess the
relationship between OT-GKR, OTR and V1aR. Interactions
between OTR residues and 4 OT-GKR amino acids Ile-3, Leu-8,
Tyr-2 and Arg-12 were observed in OTR-OT-GKR complexes.
The recognition of Ile-3 by OTR seems to be specific for OT
molecules, because this amino acid residue is absent in the cyclic
Figure 5. In response to treatment with OT or OT-X forms, GFP-P19Cl6 cells express green fluorescence driven by the
transcriptional promoter of myosin light chain-2 ventricular (MLC-2v). Fluoromicrograph (1006magnification) of day 8 cell cultures in non-
induced conditions (A) and upon induction with OT (B), OT-G (C), OT-GK (D) or OT-GKR (E). Representative flow cytometry charts of fluorescence
emitted by GFP-P19Cl6 cells at day 6 in non-induced conditions (A1) and in cultures induced by OT (B1), OT-G (C1), OT-GK (D1), and OT-GKR (E1).
Bars present quantitative analysis of fluorescence emitted by differently-stimulated GFP-P19Cl6 cells at day 6 in 3 independent experiments (F).
doi:10.1371/journal.pone.0013643.g005
Oxytocin in the Heart
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residues causes a significant decrease of affinity for OTR [36].
Usually,the OT-binding site is formed by transmembrane helices 3-
7 and extracellular loops 2 and 3 of the receptor [37]. Based on
studiesonothermembers ofthe OT-VP receptorfamily,specifically
the V1aR, it is hypothesized that that the cyclicpart of OT is lodged
in the upper third of the receptor binding pocket and interacts with
transmembrane domains 3, 4, and 6, whereas the linear C- termini
part of the OT molecule remains closer to the surface and interacts
with transmembrane domains 2 and 3, as well as with the
connecting first extracellular loop [6]. This hypothesis is supported
by various findings using site-directed mutagenesis techniques, as
well as by domain swapping experiments between the OTR and the
V2R [6,19]. In our study, molecular docking of OT and OT-GKR
showed that while both peptides are able to interact with OTR with
significant binding energies, the binding pocket for OT-GKR might
be slightly different from the binding pocket for OT. The results
demonstrate that OT-GKR can interact with several sites in
transmembrane domains 3, 4, 5 and 7 of V1aR. OT binding sites
disclosed in the V1aR model are in total agreement with those
reported by S ´lusarz et al. [38]. These results provide guidelines for
experimental site-directed mutagenesis and if confirmed, they may
be helpful in designing new selective OT analogs with agonistic
properties for OTR and V1aR.
Some data suggest that OT-GKR binding to V1aR is
functional. V1aR is present in ES D3 cells in the very early stages
of cardiac development and is then strongly down-regulated [20].
The inhibition of P19 cells differentiation involving OTA revealed
that it did not reduce the number of OT-GKR-stimulated beating
cell colonies to control levels. This indicates the presence of other
signaling pathways in response to OT-GKR. The high sequence
identity between OT and AVP receptors [39], suggest that AVP
receptors may be involved, at least in part, in OT-GKR-mediated
pathways. We observed that both V1aR antagonist as well as
V1aR silencing partially blocked the cardiomyogenic effects of
OT-GKR in EC P19 cells. The results are consistent with the
observation that OTA completely blocked OT-mediated stimula-
tion of glucose uptake in rat neonatal CM, whereas the glucose
uptake induced by OT-GKR was only partially blocked [16].
Extended C-terminal OT peptides stimulate EC P19 cell
differentiation into beating cell colonies expressing CM markers.
OT-GKR displays the highest cardiomyogenic action among OT
molecules. Both OT and OT-GKR treatment of EC P19 cells and
their derived clone, EC P19 Clone 6, expressing a GFP reporter
under the transcriptional control of the MLC-2v promoter,
produced similar morphological changes and induced GFP
fluorescence. For the moment, this action relates to differentiation
to the ventricular CM phenotype since the GFP-P19Cl6 model of
CM differentiation is controlled by the ventricle-associated MCL-
2v promoter [40]. Nevertheless, the potential of OT and OT-
GKR to promote the ventricular phenotype is of direct interest in
the development of cell therapies for the heart. Already known is a
positive effect of OT/OTR in inflammation [41,42,43]. Further-
more, recently, OT treatment had a beneficial effect in healing
myocardial infarction [26,43,44]. The clinical application of OT-
GKR in this pathology could be safe because of the specific
interaction with OTR and V1aR, as described in the present
study. The weaker effects of OT-X than OT on uterine
contractions have already been reported [45], and OT replace-
ment by OT-GKR in the therapy of cardiac pathologies could
reduce vasoconstriction attributed to V1aR activation by OT [46].
A specific question is whether the cardiomyogenic action of
OT-X is the result of cleavage to the site of OT peptide by
proteolytic activity potentially present in EC P19 cultures. In a
study by Altstein et al. [4,5], however, rat brain and plasma pro-
AVP cleavage efficiency in adults and fetuses was high (99 and
95% cleavage, respectively), resulting in the formation of fully
processed amidated AVP forms, with no detectable, partially-
processed peptides. Pro-oxytocin (pro-OT) processing in adults
was very similar (over 99% cleavage), eliciting the formation of
Figure 6. RT-PCR analysis of GATA-4 (A), Mef2c (B), myogenin (C) and MyoD (D) transcripts in EC P19 cells induced by OT or OT-GKR
in the presence or absence of OT antagonist (OTA). NI indicates non-induced controls.
doi:10.1371/journal.pone.0013643.g006
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efficiency in the fetus was very low and incomplete, culminating
in 40% unprocessed precursor and the accumulation of C-
terminally extended OT-X. In the same line of reasoning, it is
possible that OT-GKR exhibits different efficiencies compared to
OT with respect to other OT functions in the heart, such as
stimulation of ANP release [47]. If this is the case, we can
speculate that the relative levels of OT and OT-GKR (and, hence,
the relative levels of OT-processing enzymes) could have a finely-
tuned, regulatory impact on heart development and homeostasis.
Conclusion
The present study demonstrates that OT-GKR peptides have a
cardiomyogenic action via OTRs and also via V1aR. The results
raise the possibility that C-terminally extended OT molecules can
contribute to heart growth during fetal life, even if the post-
translational machinery of OT processing is not completely
developed. This cardiac OT-GKR differentiation is important in
the development of cell therapies for hearts injured by infarction,
to induce the cardiac differentiation of somatic stem cells in
diseased adult hearts for their regeneration.
Materials and Methods
High pressure liquid chromatography (HPLC) and RIA
Dried acetone-extracted homogenates were dissolved in an
aqueous solution of 20% acetonitrile containing 0.1% trifluor-
oacetic acid and applied to a Vydac 218-TP24 column
(56250 mm) for reverse-phase HPLC (Waters, Milford, MA).
The column was eluted with a linear gradient of 20–50%
CH3CN/0.1% TFA at a flow rate of 1.2 ml/min. The fractions
were collected and lyophilized in a Speed-Vac. Direct RIA [15],
after reconstitution of the samples in RIA buffer, ascertained the
presence of OT-GKR in HPLC fractions. OT-VA18 antibody was
used to measure OT-GKR concentration. Synthetic OT as well as
pituitary gland extracts, chromatographed under identical condi-
tions, served as standards [6].
Molecular docking
MolDock software investigated the interaction of OT molecules
with OTR and V1aR [48]. This program makes use of predicted
cavities during the docking process and identifies potential ligand-
binding modes (see www.molegro.com for details). 3-D models of
Figure 7. Immunofluorescence of cell differentiation markers in EC P19 cells of non-induced controls (A1-D1) and in cells
stimulated to differentiate with OT (A2-D2) and OT-GKR (A3-D3). (A4) Staining of OCT-4, a marker of the undifferentiated state. (B4)
Expression of the cardiac muscle marker dihydropyridine receptor-a1 (DHPRa1). (C4) Ventricular myosin light chain-2 ventricular (MLC-2v) protein.
(D4) Immunocytochemistry shows staining of a-actinin protein in cardiac and skeletal muscles. A4-D4 represent quantitative analysis of
corresponding markers expressed as fluorescent areas. Fluoromicrographs of cells on differentiation day 6 presented at 6100 magnification.
doi:10.1371/journal.pone.0013643.g007
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of the SYBYL molecular modeling package (Tripos Associates, St.
Louis, MO). These 3-D models of activated OTR (OTR Gq11)
and human vasopressin V1aR were described previously [38]. The
MolDock scoring function served to pre-compute score grids for
dock evaluation. Potential binding sites were detected with the
grid-based cavity prediction algorithm. The saved conformations
for ligand-receptor complexes were subjected to detailed 3-D
analysis for interactions at active sites.
Cell culture and differentiation
P19 cells (Crl-1825) from the American Type Culture
Collection (Manassas, VA, www.atcc.org) were cultured as
reported elsewhere for parental P19 cells [11]. Green fluorescent
protein (GFP)-P19Cl6 cells, a gift from Dr. C. L.Mummery
(Hubrecht Laboratory, University Medical Center, Utrecht,
Netherlands) were cultured as described for parental P19 cells
[12]. For differentiation, 1,000 cells in a volume of 25 mLo f
complete medium were plated in hanging drops onto the lid of
bacteriological grade Petri dishes (10-cm diameter) and incubated
at 37uC for 2 days in the absence (non-induced) or presence of
inducers: OT (10
–6 M, Cat. No. H-2510, Peninsula Laboratories,
San Carlos, CA, www.penlabs.com), OT-Gly, OT-Gly-Lys, OT-
Gly-Lys-Arg (synthesized by the Peptide Synthesis & Protein
Sequencing Core Facility of Eastern Quebec, Quebec, Canada),
OT antagonist (OTA) [d(CH2)5
1,Tyr(Me)
2,Thr
4,Orn
8,Tyr-NH2
9]-
vasotocin (10
26 M, Cat. No. 4015938.0005, Bachem Americas,
Inc, Torrance, CA, www.bachem.com) and selective V1aR
antagonist (V1A) d(CH2)5
1,Tyr(Me)
2,Arg
8)-vasopressin (10
26 M,
Cat. No. H-5350, Bachem). The base of each culture dish
contained phosphate-buffered saline (PBS) to prevent the drops
from evaporating. After 2 days of incubation, embryoid bodies
(EBs) formed in drops were transferred to bacterial dishes coated
with poly (2-hydroxyethyl methacrylate) (Cat. No. P3932, Sigma-
Aldrich, Oakville, ON, Canada, www.sigmaaldrich.com) to
eliminate cell adhesion to growth surfaces, with fresh differenti-
ation medium added and kept for 3 more days in suspension in the
absence (non-induced) or presence of inducers. On the 5
th day,
EBs were collected and plated in complete a-modified Eagle’s
minimal essential medium in tissue culture dishes in the absence of
inducers (NI) until day 14. The medium was refreshed every 48 h.
To analyze cardiomyogenesis in conditions of endogenous OT-
GKR production in stem cells, the OT-GKR-IRES-EGFP
construct (prepared as reported previously) [15] was transfected
into EC P19 cells with a FuGENE 6 kit (Cat. No. 11814443001,
Hoffmann-La Roche Limited, Mississauga, ON, Canada). OT-
GKR peptide levels in media secreted from control EBs at day 5
were 211.9662.5 pg/ml whereas the corresponding values
obtained in media from OT-GKR-transfected cells disclosed a
significant increment of peptide concentration to 581.3641.5 pg/
ml (n=5, p,0.05).
OTR and V1aR silencing by siRNA
OTR siRNA duplexes (sense, 5-GGA CUA CAG CAU AGA
AAU A-3; antisense, 5-UAU UUC UAU GCU GUA GUC C-3)
targeted to the 21-nucleotide mouse OTR mRNA sequence (CAG
GAC TAC AGC ATA GAA ATA). V1aR siRNA duplexes (sense,
59-CAC UGU UGU UUC UAC ACA ATT-39; antisense, 59-
UUG UGU AGA AAC AAC AGU GCT-39) to the 20-nucleotide
mouse V1aR mRNA sequence (59-AGC ACT GTT GTT TCT
ACA CAA-39) and validated siRNA negative controls (scrambled
siRNA) were designed commercially (Qiagen, Mississauga, ON,
Canada, www.qiagen.com/siRNA Cat No 1027292) and prepared
as recommended by the manufacturer. Methodology for siRNA
transfection in ES cells was adapted from a previous report [20].
Differentiating P19 cell EBs in suspension were transferred to 24-
well plates, followed by transfection with OTR siRNA (Cat.
No. SI01367779, Qiagen) and V1aR siRNA (Qiagen Cat No
SI02673083) according to the manufacturer’s instructions. After
24 h, the cells were re-transfected as before and incubated in
differentiation media in the presence or absence of OT-GKR. EB
outgrowths were examined for beating activity.
Immunocytochemistry and microscopic analysis
Cell morphology was examined under a Model IX51 inverted
microscope (Olympus, Tokyo, Japan, www.olympus.com)
equipped for epifluorescence analysis. Phase contrast micrographs
were taken with a Q Imaging QICAM-IR Fast 1394 Digital CCD
camera. At day 8, contracting cell colonies in fields of 3
independent samples were counted from the video record with
Image J software (National Institutes of Health, Bethesda, MD,
www.nih.gov). Immunocytochemistry was performed in P19 cells,
as described elsewhere [10]. The cells were incubated in 0.2%
gelatin-covered Lab-Tek plates (Cat. No. 177437, Nunc Interna-
tional, Rochester, NY, www.nuncbrand.com). They were fixed in
a solution containing 4% paraformaldehyde in 0.1 M PBS,
pH 7.4, for 10 min. They were then washed with PBS,
permeabilized for 10 min with 0.4% Triton X-100, and labeled
with specific antibodies. Anti-sarcomeric alpha-actinin monoclonal
antibody, which reacts with skeletal and cardiac muscle actinin
(clone EA-53, Cat. No. 096K4774, Sigma Chemical Co.), was
used at 1:800 dilution. Mouse monoclonal antibody IgG anti-
dihydropyridine receptor-alpha (DHPRa 20-A, Cat. No. ab2864-
100) diluted 1:200 and anti-OCT-4 rabbit polyclonal antibody
(Cat. No. ab1876-100) diluted 1:200 were both from Abcam, Inc.,
Cambridge, MA, www.abcam.com). Goat polyclonal myosin light
chain-2 ventricular (MLC-2v) (C17. Cat. No. sc-34490) was from
Santa Cruz Biotechnology, Inc. Santa Cruz Biotechnology, Santa
Cruz, CA. The Texas Red-conjugated rabbit polyclonal anti-
mouse IgG (Cat. No. ab6726-1) and sheep anti-rabbit IgG (Cat.
No. ab6793) were from Abcam, Inc (www.abcam.com). Goat anti-
mouse IgG secondary antibody conjugated to red fluorophore
Alexa Fluor 568 (Cat. No. A11004) was from Invitrogen, Life
Technologies (Carlsbad, CA). V1aR was detected by goat
polyclonal antibody C-20 (from Santa Cruz Biotech. Inc., www.
scbt.com sc- 18096 diluted 1:200. To obtain green fluorescence,
the cells were probed with secondary Alexa Fluor 488 labeled
donkey anti-goat IgG conjugate (Cat. No. A11055, Invitrogen Life
Technologies). For immunohistochemical staining, mouse embry-
os were fixed with 4% formaldehyde and 0.1% picric acid in
0.1 M PBS (pH 7.4), embedded in paraffin or sectioned using
cryostat. 5-mm sections were cut longitudinally and mounted on
polylysine-treated slides (Cat. No. P-4981, Esco, Erie Scientific
Co., Portsmouth, NH). OTRs were detected by rabbit antibody
(Cat. No. RDI-OXYTOCRabrx, RDI Division of Fitzgerald
Industries International, Concord, MA, www.researchd.com/
miscabs/oxytocr.htm) diluted 1:700. OT-specific antibodies could
be divided into those that only recognized C-terminally amidated
forms (OT-MM, a generous gift from Dr. Mariana Morris of
Wright State University, Dayton, OH) and those that recognized
also C-terminally extended peptides (OT-VA18) characterized in
Dr. H. Gainer’s Laboratory of Neurochemistry, National Institutes
of Health, Bethesda, MD) [1]. Polyclonal rabbit antibody
specifically recognizing OT-GKR peptide (VA18, a generous gift
from Dr. Gainer), was diluted 1:700. Staining was revealed by the
biotin-streptavidin method with Histostain Plus Rabbit Primary
3,39-diaminobenzidine (DAB) kit (Cat. No. 85-9243, Zymed
Laboratories, San Francisco, CA, www.zymed.com), counter-
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procedures. After reaction with anti-OT-GKR antibodies, cryostat
cardiac sections were probed with Texas Red-labeled goat anti-
rabbit IgG conjugate (1:200; Cat. No. ab6793, Abcam, Inc.).
Monoclonal antibody against cardiac troponin (1:100, Cat.
No. ab7217-7, Abcam, Inc.) was deployed for CM identification.
To obtain green fluorescence, secondary biotinylated rabbit
antibody against mouse IgG (BA-2001, Horse Vector Laborato-
ries, Burlingame, CA) was followed by streptavidin-Alexa Fluor
488 conjugate (S11223, Invitrogen Life Technologies). Control
staining, obtained by overnight pre-incubation of anti-OT-GKR
antibody at 4uC in the presence of 10
–6 M synthetic OT-GKR or
the omission of primary antibodies, was negative, emphasizing
specificity of immunocytochemistry. Panoramic, cross-sectional,
digital images of stained whole embryos were prepared with
Adobe Photoshop CS software (Adobe Systems Inc., San Jose,
CA).
For transferase dUTP nick end labeling (TUNEL) reaction
indicative of apoptosis, the DeadEnd Fluorometric TUNEL
System (Cat. No. G3250, Promega, Montreal, QC, Canada) was
used.
Fluorescence-activated cell sorting (FACS) analysis
GFP-P19Cl6 cell culture was digested to single-cell suspension
with Accutase (Cat. No. AT104, Innovative Cell Technologies,
Inc., San Diego, CA, www.innovativecelltech.com) for adhered
cells (days 6 and 14) or Accumax (Cat. No. AM105, Innovative
Cell Technologies, Inc.) for suspended EBs (day 5 of differenti-
ation). The dissociated cells were washed with PBS, suspended in
PBS containing Ca
2+ (1 mM) and Mg
2+ (0.5 mM) at room
temperature, and filtered with a cell strainer with 70 mm nylon
mesh (Falcon, Cat. No. 352360, BD Biosciences, Mississauga,
ON, Canada, www.bdbiosciences.ca). GFP-positive cells were
quantified by the passage of minimum 10,000 viable cells and
sorted in the FL1 channel on the basis of forward-scattered and
side-scattered light in a FACS Aria
TM Cell Sorter (BD Biosciences)
as the cells traversed the beam of an argon ion laser (488 nm). The
BD Biosciences software program CellQuest was applied for data
acquisition and analysis. Non-induced cells served as negative
controls. Sorted GFP-positive cells were collected in culture media
and allowed to reattach to culture dishes, at least for the
confirmation of beating contractility.
Reverse transcription-polymerase chain reaction (RT-PCR)
Total cellular RNA was extracted with TRIzol Reagent (Cat.
No. 15596-018, Invitrogen Life Technologies) according to the
manufacturer’s protocol. To remove genomic DNA, total RNA
was treated with 2 units of Turbo DNase (Turbo DNA-free, Cat.
No. AM1907, Applied Biosystems/Ambion. Streetsville, ON,
Canada). First-strand cDNA was synthesized in a final volume of
40 ml containing first-strand buffer, 4 mg of cellular RNA, 4 mlo f
hexanucleotide primers (Cat. No. 588753, Invitrogen Life Tech-
nologies) and avian myeloblastosis virus reverse transcriptase (12
units/mg RNA, Cat. No. 28025-013, Invitrogen Life Technolo-
gies) for 180 min at 37uC. First-strand cDNA (5 ml) was then
utilized for PCR amplification with exon-specific oligonucleotide
primers in a Robocycler Gradient 40 thermocycler (Stratagene, La
Jolla, CA). For all PCR studies, the number of cycles employed
was within the linear range of amplification. These values were
normalized to corresponding 18S mRNA. Primer sequences and
conditions for the PCR analysis of 143-bp GATA-4 NM_008092
(annealing temperature 61uC, 32 cycles), 57-bp Mef2c
NM_025282.1 (annealing temperature 60uC, 34 cycles), 272-bp
Myogenin NM_008092 (annealing temperature 54uC, 18 cycles)
and 144-bp MyoD NM_010866 (annealing temperature 54uC, 30
cycles) mouse transcripts have already been described [12]. The
PCR products were size-fractionated by 2% agarose gel
electrophoresis and visualized with the Storm 840 Imaging System
and ImageQuant software (Version 4.2, Molecular Dynamics Inc.,
Sunnyvale, CA).
Statistics
The results are expressed as mean 6 SEM. Comparisons
between groups were evaluated by 1-way ANOVA, followed by
Newman-Keuls multiple comparison test with the PRISM
computer program. Statistical significance was taken as p,0.05.
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